Pfizer and BioNTech have announced they will supply an additional 100 million doses of COMIRNATY, the companies’ COVID-19 vaccine, to the 27 European Union (EU) member states in 2021.
This announcement is a result of the European Commission’s (EC) decision to exercise its option to purchase an additional 100 million doses under its expanded Advanced Purchase Agreement signed on February 17, 2021. This brings the total number of doses to be delivered to the EU to 600 million.
“We remain committed to moving as quickly and safely as possible to bring this vaccine to more people in Europe, as the deadly virus continues to wreak havoc across the continent,” says Albert Bourla, Chairman and Chief Executive Officer, Pfizer. “To date, we have met all of our supply commitments to the EC and we plan to deliver 250 million doses to the European Union in Q2, a four-fold increase on Q1’s agreed quantity.”
COMIRNATY will be produced in BioNTech’s and Pfizer’s manufacturing sites in Europe.